Recent Security Class Actions

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NYSE: GSK)

35 Days left to seek lead plaintiff status.

Company Name:GSK plc American Depositary Shares (Each representing two Ordinary Shares)
Stock Symbol:NYSE: GSK
Class Period Start:02/05/2020
Class Period End (inclusive):08/14/2022
Filing Deadline:04/07/2025

The complaint alleges that, throughout the Class Period, Defendants represented to investors that GSK removed Zantac from the market “[b]ased on information available at the time and correspondence with regulators,” and that GSK was “continuing with investigations into the potential source of NDMA.” Defendants also assured investors that “GSK, the FDA, and the EMA [European Medicines Agency] have all independently concluded that there is no evidence of a causal association between ranitidine therapy and the development of cancer in patients,” findings that were “consistent with other ranitidine data published prior to 2019.” Finally, Defendants claimed that they could not “quantify or reliably estimate the liability” GSK could face from Zantac-related legal proceedings.

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NYSE: GSK) Claim Form

Name(Required)
Address
This field is for validation purposes and should be left unchanged.